Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FSFG8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,365
Award facts
- Contract value 100% obligated
- $12,364.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $12,364.81 to DMS Pharmaceutical Group Inc. for 60 tablets of Jakafi 10 mg, with a completion date of December 31, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. This delivery order was issued under the company's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical supply chain operations for Department of Defense healthcare facilities.
The PPV-G GEN V contract represents a strategic initiative to consolidate pharmaceutical sourcing across the military medical system, with DMS Pharmaceutical Group serving as one of multiple regional prime vendor contractors. The company's IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, comprising a 30-month base period and three 30-month option periods. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated substantial performance across multiple therapeutic categories and product lines, positioning it to fulfill diverse and specialized pharmaceutical requirements for Department of Defense military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FSFG8?
SPE2DR26FSFG8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FSFG8 worth?
The government has obligated $12,365 on SPE2DR26FSFG8.
Is contract SPE2DR26FSFG8 an order under another contract?
Yes. SPE2DR26FSFG8 is a delivery order under SPE2DR25D9313, an indefinite delivery contract.
Was contract SPE2DR26FSFG8 competed?
The extent of competition for SPE2DR26FSFG8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award